Investigation of female survival benefit in metastatic melanoma
Open accessThe DOI matches its Crossref record.
Abstract
Epidemiological studies show female survival benefit in advanced metastatic melanoma. In investigating a possible mechanism for this female survival benefit, we have previously reported that the female steroid 17beta-oestradiol significantly reduces invasion of a human melanoma cell line (A375-SM cells) and ocular melanoma cells through fibronectin. Neither cell type was found to possess oestrogen receptor-alpha. The aim of the current study was to obtain further information on the extent to which progression of cutaneous melanoma might be sex steroid sensitive by (a) examining the relationship between circulating sex steroids, sex hormone binding globulin and disease progression; (b) examining the relationship between sex steroid structure and the ability of steroids to reduce invasion of a melanoma cell line in vitro; and (c) examining the effects of sex steroids on proliferation of these cells in vitro. We report a significant reduction in circulating oestrone with disease progression in male but not female patients. Examining steroids for their ability to inhibit invasion of A375-SM cells through fibronectin in vitro, oestrogenic compounds (17beta-oestradiol and oestrone) were found to inhibit invasion; in this respect, oestrone was approximately 50 times more potent than 17beta-oestradiol; steroids lacking the benzene ring structure did not inhibit invasion, indeed dehydroepiandrosterone (DHEA) which acts as a precursor to androgenic steroids significantly enhanced invasion. Proliferation of A375-SM cells was unaffected by 17beta-oestradiol, oestrone or dihydrotestosterone when cells were cultured on plastic; in contrast, all three steroids induced modest proliferation of cells when grown on fibronectin with dihydrotestosterone the most mitogenic of the three steroids. These data are consistent with sex steroids playing a role in melanoma progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Role of estrogen receptors in health and disease
Chen, P., Li, B., & Ou-Yang, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.839005 · Cited by 339
Gender Differences in Melanoma Survival: Female Patients Have a Decreased Risk of Metastasis
Joosse, A., de Vries, E., Eckel, R., Nijsten, T., Eggermont, A. M. M., Hölzel, D., Coebergh, J. W. W., & Engel, J. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.354 · Cited by 266
Gender medicine and oncology: report and consensus of an ESMO workshop
Wagner, A. D., Oertelt-Prigione, S., Adjei, A., Buclin, T., Cristina, V., Csajka, C., Coukos, G., Dafni, U., Dotto, G.-P., Ducreux, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz414 · Cited by 214
Oestrogen functions in skin and skin appendages
Thornton, M. J. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.3.617 · Cited by 82
“Oestradiol can also inhibit the invasion of human melanoma cells through fibronectin [119], and athymic mice carrying an oestrogen-receptor-positive human melanoma cell line show a sex-dependent increase in tumour latency and an overall inhibition of tumour growth following treatment with oestradiol [116].”
BackgroundSex disparities in melanoma outcomes: The role of biology
Nosrati, A., & Wei, M. L. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.06.018 · Cited by 66
Metadata
- Authors
- Richardson, B., Price, A., Wagner, M., Williams, V, Lorigan, P., Browne, S., Miller, J. G., & Neil, S. M.
- Venue
- British Journal of Cancer
- Published
- 1999-07-30
- Volume
- 80
- Issue
- 12
- Pages
- 2025-2033
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2051247852
- Cited by
- 62
- References
- 0
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.